Mylan (MYL) Comments on Unfavorable Copaxone Ruling; Reaffirms Expectations for No EPS Impact

Go back to Mylan (MYL) Comments on Unfavorable Copaxone Ruling; Reaffirms Expectations for No EPS Impact